Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 35.845 4.78% 1.64
AGIO closed down 0.32 percent on Thursday, November 14, 2019, on 78 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical AGIO trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 4.78%
Stochastic Reached Overbought Strength 4.78%
Weak + Overbought Other 4.78%
Overbought Stochastic Strength 4.78%
Crossed Above 50 DMA Bullish 4.44%
NR7 Range Contraction 4.44%
50 DMA Resistance Bearish 5.46%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.46%
Crossed Above 20 DMA Bullish 5.46%
Outside Day Range Expansion 5.46%

Older signals for AGIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Chemistry Biopharmaceutical Cancer Cancers Organic Chemistry Inborn Errors Of Metabolism Agios Pharmaceuticals
Is AGIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 70.7
52 Week Low 28.36
Average Volume 815,116
200-Day Moving Average 47.7992
50-Day Moving Average 34.0094
20-Day Moving Average 33.042
10-Day Moving Average 33.822
Average True Range 1.8809
ADX 22.17
+DI 17.9383
-DI 22.3373
Chandelier Exit (Long, 3 ATRs ) 29.9073
Chandelier Exit (Short, 3 ATRs ) 34.0027
Upper Bollinger Band 35.2006
Lower Bollinger Band 30.8834
Percent B (%b) 0.77
BandWidth 13.065795
MACD Line -0.0095
MACD Signal Line -0.2881
MACD Histogram 0.2786
Fundamentals Value
Market Cap 1.66 Billion
Num Shares 48.4 Million
EPS -6.33
Price-to-Earnings (P/E) Ratio -5.40
Price-to-Sales 59.19
Price-to-Book 6.21
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.51
Resistance 3 (R3) 36.42 35.55 36.13
Resistance 2 (R2) 35.55 34.96 35.60 36.00
Resistance 1 (R1) 34.88 34.60 34.45 34.98 35.87
Pivot Point 34.02 34.02 33.80 34.06 34.02
Support 1 (S1) 33.35 33.43 32.91 33.44 32.55
Support 2 (S2) 32.48 33.07 32.53 32.42
Support 3 (S3) 31.81 32.48 32.29
Support 4 (S4) 31.91